Skip to content

Advertisement

  • Commentary
  • Open Access

Should hydroxyethyl starch solutions be totally banned?

  • 1Email author,
  • 2,
  • 3 and
  • 4
Critical Care201317:193

https://doi.org/10.1186/cc13027

  • Published:

Abstract

The choice of which intravenous solution to prescribe remains a matter ofconsiderable debate in intensive care units around the world. Trends have been movingaway from using hydroxyethyl starch solutions following concerns about safety. Butare the available data sufficient to clearly assess the risk-benefit balance for allpatients, and is there enough evidence of harm to justify removing these drugscompletely from our hospitals?

Keywords

  • Hydroxyethyl Starch
  • Positive Fluid Balance
  • Intravenous Solution
  • Intravenous Fluid Therapy
  • Initial Lactate

The choice of which intravenous solution to prescribe is a question that arises manytimes a day in every intensive care unit around the world. The pendulum has beenswinging away from hydroxyethyl starch (HES) solutions, in part because of therevelations of fraudulent studies conducted by Joachim Boldt [1]. Indeed, the persistence of HES molecules in the body is of serious concernand this issue can no longer be ignored by use of ‘newer’ starches. However,for any intravenous solution (as for any drug), a balance between risks and benefit mustbe considered. After all, diuretics, angiotensin-converting enzyme inhibitors, andbeta-blocking agents can alter renal function in some patients but are also highlyeffective agents in the management of the cardiac patient.

Recent studies have provided a wealth of evidence documenting the adverse effects of HESsolutions, but can they justify complete removal of these drugs from the market? Such adecision would seem to require evidence of harm in excess of benefit. Let’s try toassess this balance (Figure 1) given the data provided bythese recent studies.
Figure 1
Figure 1

Benefits and risks of hydroxyethyl starch (HES) solutions.

Was the harm signal robust?

The effects of HES solution on renal function in the Crystalloid versus HydroxyethylStarch Trial (CHEST) [2] were somewhat discordant. The increase in creatinine with HES was relativelyminor and urine output was initially greater, so there was actually less acute kidneyinjury when assessed by the R and I stages of the Risk, Injury, Failure, Loss, andEnd-stage renal disease criteria. There was a greater use of renal replacement therapy,but the difference concerned only 39 of 7,000 patients. The toxicity of HES solutions inthe Volume Substitution and Insulin Therapy in Severe Sepsis [3] and 6S (Scandinavian Starch for Severe Sepsis/Septic Shock trial) [4] studies was more apparent, but much larger doses (in some cases well inexcess of recommendations or common practice) were used.

Are the alternatives so safe?

Even if we accept the toxicity of HES solutions, the relative safety of other solutionsis not entirely clear. Gelatin solutions have not been well studied, but there do appearto be concerns for renal toxicity [5]. Similarly, there is a renal failure risk associated with excessiveadministration of other colloids [5]. With their high chloride load, 0.9% saline solutions may also cause harm,including an increased risk for dialysis [6, 7]. Finally, hypotonic solutions, such as lactated Ringer’s orHartmann’s solution, may not be desired, and the effects of some constituents,including acetate and gluconate, of other balanced solutions have not been well studied.Although both the CHEST [2] and 6S [4] trials provide evidence of comptive toxicity for saline versus HES in salineand Ringer’s acetate versus HES in the same carrier, no available intravenoussolution is free of potential adverse effects.

Do the available studies allow us to evaluate benefit?

If we are to judge the risk-benefit ratio for each of the available fluids, we cannotlook only at studies evaluating toxicity. HES, like other colloids, is believed toprovide benefit by improving the efficiency of resuscitation [8]. Efficiency, in this context, is the time to reach resuscitation goals andthe volume of fluid required to achieve these goals. To some extent, this was documentedin the CHEST trial [2], in which the administration of HES resulted in an initially greater urineoutput, a less positive fluid balance, a higher central venous pressure, and lowerrequirements for vasopressor agents. Furthermore, the recent Colloids Compared toCrystalloids in Fluid Resuscitation of Critically Ill Patients study, which included3,000 patients, showed a less positive fluid balance and lower 90-day mortality rates incolloid than in crystalloid-treated patients, and the colloids administered wereprimarily synthetic (Djillali Annane, personal communication). In contrast, the 6S study [4] could not evaluate efficiency of resuscitation, because patients had largelyalready achieved resuscitation goals prior to enrolment. In both studies, the centralvenous oxygen saturation was 74% at baseline, and the initial lactate level was only 2mEq/L in the 6S study.

Thus, the recent trials, though excellent, provide only half the information we need tobe able to assess a risk-benefit relationship. These studies have clearly characterizedthe toxic effects of HES solutions but do not inform on potential benefit, except todemonstrate that giving fluids to already-resuscitated patients does not provide any!None of the intravenous fluids currently available may be entirely safe, especially whengiven in large amounts. All fluids should be considered as drugs, and no drug isrisk-free. Indeed, one can consider that even oral fluids have their risks: beer, wine,and non-alcoholic beverages, such as coffee and sugar-containing beverages, should allbe taken only in moderation, and even water can be harmful if taken in excess.

Conclusions

We believe that decisions about intravenous fluid therapy should be individualized onthe basis of the available evidence and the clinical context. Clinicians must definitelybe aware of the harmful effects attributable to HES, and use of these solutions inpatients with sepsis or in bleeding patients should be undertaken only with extremecaution and only when the benefits for the individual patient are expected to exceed therisks for that individual. Eliminating these solutions completely, on the other hand,prevents their use even in situations in which they are judged by physicians to have apositive benefit-to-risk relationship. We believe that the US Food and DrugAdministration has made the right decision in leaving the current HES solutionsavailable but making specific recommendations regarding restricted use of thesesolutions in certain groups of patients and adding a ‘black box’ warningabout risks of excessive bleeding [9]. This approach represents good regulatory medicine because it does notimpinge on provider autonomy but ensures improved patient safety. We hope the EuropeanMedicines Agency will take a similar view.

Abbreviations

6S: 

Scandinavian Starch for Severe Sepsis/Septic Shock trial

CHEST: 

Crystalloid versusHydroxyethyl Starch Trial

HES: 

hydroxyethyl starch.

Declarations

Authors’ Affiliations

(1)
Department of Intensive Care, Erasme Hospital Université libre de Bruxelles, route de Lennik 808, Brussels, 1070, Belgium
(2)
Department of Critical Care Medicine, School of Medicine, Room 608 Scaife Hall 3550 Terrace Street, Pittsburgh, PA 15261, USA
(3)
Department of Anesthesiology and Critical Care Medicine, Duke University MedicalCenter/Durham VAMC, Durham, NC 27710, USA
(4)
UCLH/UCL NIHR Biomedical Research Centre, Maple House 149 Tottenham Court Road, London, W1T 7DN, UK

References

  1. Wise J: Boldt: the great pretender. BMJ 2013, 346: f1738. 10.1136/bmj.f1738View ArticlePubMedGoogle Scholar
  2. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA: Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012, 367: 1901-1911. 10.1056/NEJMoa1209759View ArticlePubMedGoogle Scholar
  3. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358: 125-139. 10.1056/NEJMoa070716View ArticlePubMedGoogle Scholar
  4. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J: Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012, 367: 124-134. 10.1056/NEJMoa1204242View ArticlePubMedGoogle Scholar
  5. Davidson IJ: Renal impact of fluid management with colloids: a comptive review. Eur J Anaesthesiol 2006, 23: 721-738. 10.1017/S0265021506000639View ArticlePubMedGoogle Scholar
  6. Shaw AD, Bagshaw SM, Goldstein SL, Scherer LA, Duan M, Schermer CR, Kellum JA: Major complications, mortality, and resource utilization after open abdominalsurgery: 0.9% saline compared to Plasma-Lyte. Ann Surg 2012, 255: 821-829. 10.1097/SLA.0b013e31825074f5View ArticlePubMedGoogle Scholar
  7. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M: Association between a chloride-liberal vs chloride-restrictive intravenous fluidadministration strategy and kidney injury in critically ill adults. JAMA 2012, 308: 1566-1572. 10.1001/jama.2012.13356View ArticlePubMedGoogle Scholar
  8. Kellum JA, James MF: Why do intensivists still use hydroxyethyl starch? Crit Care Med 2010, 38: 2260-2262. 10.1097/CCM.0b013e3181f8fa15View ArticlePubMedGoogle Scholar
  9. US Food and Drug Administration: FDA Safety Communication: boxed Warning on increased mortality and severe renalinjury, and additional warning on risk of bleeding, for use of hydroxyethyl starchsolutions in some settings. http://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm358271.htm#professionals

Copyright

© BioMed Central Ltd. 2013

Advertisement